Alfadoxin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alfadoxin

Quick Facts

Property Description
Active ingredient Doxazosin
Form Oral Tablet (standard and modified-release)
Pharmacological class Alpha-1 adrenoceptor antagonist
Common purpose Management of high pressure and obstructive urinary symptoms
Origin Synthetic, Quinazoline derivative

What is Alfadoxin?

Alfadoxin is a prescription medication whose active substance is Doxazosin, a compound belonging to a specific class of agents known as alpha-1 adrenoceptor antagonists, or alpha-1 blockers. As a synthetic quinazoline derivative, its structure has been clinically recognized for its selective action on specific nerve receptors, which forms the basis of its therapeutic use. The core function of Alfadoxin is to influence the smooth muscle tone of blood vessels and certain tissues, a mechanism that supports its dual general application.

What Pharmacological Class Does Alfadoxin Belong To?

Alfadoxin is definitively categorized as an alpha-1 blocker, a group of drugs that reduce vascular resistance and relax smooth muscle by blocking specific nerve receptors. The active ingredient is Doxazosin mesylate, which is formulated as a single active ingredient product for oral administration. This class of medication induces vasodilation, promoting the widening of blood vessels. This mechanism provides the recognized benefit of lowering systemic pressure. Alfadoxin is often presented as a treatment option where its ability to influence both blood pressure and lower urinary tract function is desirable, differentiating it from agents with a singular focus.

Composition and Available Dosage Forms

The primary dosage forms available are the standard oral tablet and, notably, the modified-release tablet (or extended-release formulation). This modified-release profile is a key feature, as it is designed to ensure the Doxazosin is delivered gradually into the system, offering a sustained effect over time. This class of medication is effective in relaxing smooth muscle in the genitourinary tract. The general benefit of Alfadoxin is its established ability to help normalize systemic pressures and ease obstruction-related symptoms by promoting the relaxation of muscular tissues.

What side effects are possible with Alfadoxin?

Possible Side Effects and Safety Information for Alfadoxin

Official safety documentation categorizes the risks associated with Alfadoxin, an alpha-blocker, primarily around its effects on blood pressure and heart function.

Adverse Reaction Scope

The most Very Common side effects (affecting ge 10%) include dizziness, headache, and fatigue. Common reactions ( 1% to 10%) include syncope (fainting), postural hypotension (a drop in blood pressure upon standing), gastrointestinal disturbances like constipation, and upper respiratory tract infections.

Serious and Clinically Significant Adverse Reactions

High-level safety warnings highlight the risk of postural hypotension and syncope, particularly after the first dose or a dose increase. Rare but serious reactions that require immediate medical attention include priapism (a prolonged, painful erection) and severe allergic reactions such as angioedema. Cardiovascular risks, including the onset or worsening of angina pectoris and atrial fibrillation, have been reported in post-marketing surveillance.

Safety Restrictions and Monitoring

Contraindications: Alfadoxin is restricted for use in patients with moderate to severe hepatic (liver) impairment and is contraindicated when co-administered with strong CYP3A4 inhibitors (which increase drug levels and toxicity risk) or other alpha-adrenergic antagonists.

Population-Specific Warnings: Caution is advised when prescribing to patients with severe renal (kidney) impairment or certain pre-existing heart rhythm conditions (QT prolongation). The drug is for use in men only. Patients scheduled for cataract surgery must inform their ophthalmologist of current or past Alfadoxin use due to the documented risk of Intraoperative Floppy Iris Syndrome (IFIS).

Exposure Patterns: The risk of hypotension-related symptoms like dizziness is highest at treatment initiation and when the dose is increased. Safety monitoring is required for blood pressure changes and symptoms of serious reactions like priapism, angina, or severe allergic responses.

Overdose and Emergency Response

Overdose and When to Seek Help

The overdose profile for Alfadoxin (Doxazosin) is defined by the severe consequences of its pharmacological effect, primarily presenting as profound hypotension, a significant and potentially life-threatening drop in blood pressure. Regulatory documents confirm that the most likely manifestation of overdosage is this marked decrease in systemic pressure. Other officially documented clinical signs include drowsiness and documented changes in heart rate.


Documented Manifestations and Severe Outcomes

Profound hypotension can lead to serious circulatory compromise. Official regulatory summaries note that severe consequences, including syncope (loss of consciousness) and grand mal seizure, have been reported in association with severe hypotensive events.


Required Emergency Action

Immediate medical assistance is mandated in the event of an overdose. The official guidance is to seek emergency medical assistance or call a Poison Control Center immediately. If an individual has collapsed, experienced a seizure, or cannot be awakened, emergency services must be contacted without delay.

Management for an overdose is strictly symptomatic and supportive. Treatment involves close monitoring of vital signs and corrective measures, such as the intravenous infusion of fluid, aimed at restoring blood pressure. It is officially stated that no specific antidote is known, and due to the drug’s high protein binding, dialysis is not indicated as a procedural treatment measure.

Therapeutic Uses of Alfadoxin

What Alfadoxin Treats: Main Uses and Benefits

Alfadoxin (Doxazosin) is primarily indicated for two distinct but commonly coexisting chronic conditions, generally providing support for symptom management across both the cardiovascular and urological systems. Alfadoxin is indicated for the treatment of both hypertension and the signs and symptoms of Benign Prostatic Hyperplasia.

This medication is commonly used to help manage the overall symptom load across conditions characterized by elevated systemic pressures and symptoms related to physical discomfort stemming from urinary issues. Specifically, Alfadoxin is relevant for easing the primary symptoms of essential hypertension and Benign Prostatic Hyperplasia (BPH).

Managing Symptom Domains

Alfadoxin’s therapeutic action supports patients in two key areas. For chronic high blood pressure, its benefit is the sustained lowering of elevated systemic pressures (systolic and diastolic), which generally helps support vascular function and may assist in easing the overall cardiovascular risk burden over time. For BPH, it is commonly used to help ease the obstructive and irritative symptoms, including urinary hesitancy, weak flow, and nocturia. This dual utility means it is often applied in scenarios where patients experience both conditions concurrently, which may contribute to easing the complexity of the overall management plan.


Quick Fact: Relief for Obstructive and Irritative Symptoms
Primary Urinary Symptoms Eased Urinary hesitancy, weak stream, incomplete bladder emptying, and frequent nighttime urination (nocturia).
Vascular Symptom Axis Elevated systemic pressures (hypertension).

Regulatory References

  1. NIH DailyMed labeling

Eligibility and Restrictions for Use

The regulatory profile for Alfadoxin (Doxazosin) establishes which patient populations are permitted, restricted, or prohibited from using the medication, based on official labeling.

Eligible Use

Alfadoxin is approved for use in adults (18 years and older) for the treatment of essential hypertension and symptomatic Benign Prostatic Hyperplasia (BPH). Use is generally considered acceptable in patients with renal impairment, although administration requires careful consideration.

Mandatory Exclusions (Contraindications)

The medicine must not be used by individuals with a known hypersensitivity to doxazosin or related quinazolines. It is also contraindicated for patients with a documented history of orthostatic hypotension and for BPH patients with complications such as overflow bladder, anuria, or concurrent hypotension.

Population Restrictions

Use is not recommended for the pediatric population (under 18) as safety and efficacy have not been established. Patients with severe hepatic impairment are also not recommended for treatment, and caution is required for those with milder liver dysfunction. For pregnancy, use is conditional on the benefit outweighing the potential risk; use during lactation is generally not advised. Patients undergoing cataract surgery must inform their surgeon of past or current use.

What should I know about interactions with other medicines?

Alfadoxin's (Doxazosin) official interaction profile is characterized by two main documented concerns: interactions that enhance blood pressure lowering and those that increase drug exposure.

Documented Interaction Patterns

Interaction Type Interacting Agents / Classes Officially Documented Effect Regulatory Restriction
Pharmacodynamic PDE-5 Inhibitors (e.g., sildenafil, tadalafil, vardenafil) Additive blood pressure lowering and symptomatic hypotension. Respect a 6-hour time interval between Alfadoxin and PDE-5 inhibitor intake to reduce hypotension risk.
Pharmacodynamic Other Antihypertensives Potentiation of the blood pressure lowering activity. Use with caution.
Pharmacokinetic Strong CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir) Potential for increased systemic exposure to Doxazosin due to reduced metabolism via CYP3A4. Caution is formally advised.
Pharmacokinetic Cimetidine (H2-Antagonist) Resulted in a 10% increase in the mean AUC (exposure) of Doxazosin. No specific restriction.

Population-Specific Cautions

Official labeling advises particular caution when administering Alfadoxin to patients with impaired hepatic function due to the drug's extensive liver metabolism. Furthermore, for the modified-release formulation, markedly prolonged gastrointestinal retention times may lead to increased systemic exposure to Doxazosin. No specific interactions with food, alcohol, or herbal products are formally mandated in the regulatory labels reviewed.

Mechanism of Action

How Alfadoxin Works: Pharmacodynamic Mechanism

Alfadoxin acts as a competitive antagonist at the postsynaptic alpha1-Adrenoceptors (alpha1-ARs) found on smooth muscle cells throughout the vascular and genitourinary systems. This molecular action involves blocking the binding site for the endogenous neurotransmitter Norepinephrine, thereby neutralizing the signal that triggers muscle contraction. The blockade functionally prevents the activation of the internal Gq-protein signaling cascade.

This mechanism results in the relaxation of smooth muscle tone in two distinct systems. Systemically, the relaxation of vascular smooth muscle causes vasodilation and a resultant reduction in Total Peripheral Resistance (TPR). Locally, the relaxation of smooth muscle in the prostatic capsule and bladder neck structurally decreases resistance to outflow in the lower urinary tract. The drug's long half-life supports sustained alpha1-AR saturation, maintaining continuous physiological modulation.

Dosage and Administration Information

Alfadoxin is a medication administered orally and is available in both an Immediate-Release (IR) tablet and a Prolonged-Release (XL/GITS) tablet form. Usage patterns are defined by the clinical indication and the specific formulation.

All approved regimens require once daily administration. For the treatment of hypertension with the IR tablet, the initial dose is 1 mg once daily, and the dosage may be gradually increased up to a maximum of 16 mg per day. For Benign Prostatic Hyperplasia (BPH), the starting dose is 1 mg (IR) or 4 mg (XL) once daily, with the maximum daily dose limited to 8 mg for both forms.

Dosage adjustments (titration) must be performed slowly and methodically. For the IR tablet, dose increases should not occur more frequently than every one to two weeks. The prolonged-release tablet requires a longer interval, with increases limited to every three to four weeks. The IR tablets may be taken with or without food, though the initial dose for hypertension is often taken before retiring to bed. The XL/GITS tablets, conversely, must be taken with breakfast to maintain a consistent absorption profile.

A crucial administration requirement for the XL/GITS tablet is that it must not be chewed, divided, cut, or crushed to protect the controlled-release delivery system. If Alfadoxin use is interrupted for several days, guidelines mandate that therapy must be restarted using the initial dosing regimen (1 mg or 4 mg) before re-titration. Use in patients with hepatic impairment requires particular caution and careful dose titration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Alfadoxin

Alfadoxin (Doxazosin) was studied for its use in managing two main health issues: symptoms related to the prostate gland and high blood pressure. The research base is made up primarily of Randomized Controlled Trials (RCTs), considered the standard of evidence, alongside pooled analyses and long-term observational studies. This overview describes what the research has explored and where evidence remains limited, without offering any clinical advice.


Evidence for Managing Symptoms of Benign Prostatic Hyperplasia (BPH)

Research was evaluated in adult men experiencing outcomes related to physical discomfort and difficulties when urinating due to BPH. Short-term RCTs typically cover 12 to 16 weeks and were used in research exploring how symptoms change over time compared to a placebo. Researchers monitored patient-reported outcomes using standardized tools and examined functional measures, like how quickly urine flows. Research observed changes in symptom scores and urine flow measurements.


Evidence for Managing Essential Hypertension (High Blood Pressure)

Alfadoxin was studied for its application in adults with conditions involving periods of heightened symptoms related to high blood pressure. Studies explored the effect of Alfadoxin compared to placebo and against other medications. Trial reports data show patterns related to the measurements of blood pressure changes. However, the conclusions that can be drawn about Alfadoxin for general, uncomplicated hypertension are limited by the findings of one long-term trial, which described a noted imbalance in specific cardiovascular outcomes.


Research on Dual Management of BPH and Hypertension

Research was evaluated in a specific population of adult men who had been diagnosed with both symptomatic BPH and coexisting hypertension. In these research scenarios, studies monitored both patient-reported outcomes related to lower urinary tract symptoms (LUTS) and objective measures of blood pressure at the same time. The evidence for this co-morbid population is partly derived from observational studies and subgroup analyses.


Research Gaps and Areas of Scientific Uncertainty

The research highlights what is known—and what is still uncertain—about Alfadoxin. Key gaps exist in the long-term, controlled data for its cardiovascular use, where certainty remains low due to early cessation of a major trial. Comparative evidence is lacking for certain outcomes when comparing Alfadoxin directly against every alternative treatment. While studies contribute to the broader evidence landscape, they do not determine whether an individual will respond similarly, and research is ongoing in many areas related to long-term monitoring.

Key Studies & References

  1. Regulatory Document: Doxazosin FDA Prescribing Information (Label)

Frequently Asked Questions (FAQ)

Common questions about Alfadoxin (FAQ)


Q: Is Alfadoxin meant for long-term or short-term use?

Official product information indicates that treatment with Alfadoxin is typically intended to be a long-term approach. As the drug is commonly used to manage chronic conditions like high blood pressure and Benign Prostatic Hyperplasia (BPH), its use is often intended to be sustained over time.


Q: Are the side effects temporary, or will they last for the entire course of treatment?

Studies suggest that while certain common side effects may occur early in treatment, they may diminish or become less frequent as the body adjusts to the medication. If a side effect persists or becomes bothersome, consulting a healthcare provider may be appropriate.


Q: Is there any evidence of long-term problems or issues with Alfadoxin?

Official long-term animal studies noted an increased incidence of heart muscle damage (myocardial necrosis or fibrosis). However, regulatory documents clarify that the clinical significance of these specific findings in humans is currently unclear.


Q: Can I take over-the-counter painkillers or other medicines with Alfadoxin?

According to official sources, common over-the-counter pain relievers known as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may affect blood pressure and are advised to be kept to a minimum while taking Alfadoxin. Other common non-prescription pain relievers like paracetamol or codeine can generally be taken safely.


Q: Can I take vitamins or supplements, like Omega-3 or Vitamin D, with Alfadoxin?

Regulatory sources indicate there is not enough official information available to confirm the potential for interactions or the use of most herbal remedies or dietary supplements with this medication. This means their specific interaction profile is largely unknown.


Q: Are there any specific food restrictions when taking Alfadoxin?

Official administration instructions describe different rules for different tablet forms. The extended-release tablet form of Alfadoxin must be taken with breakfast. Conversely, the immediate-release tablet form may be taken with or without food.


Q: How soon after taking Alfadoxin will I notice a benefit or feel a difference?

For high blood pressure management, the maximum reduction in pressure typically occurs 2 to 6 hours after dosing. For the relief of Benign Prostatic Hyperplasia (BPH) symptoms, improvement may take up to two weeks after starting treatment.


Q: What is the general timeframe for a course of treatment?

According to regulatory guidance, treatment with Alfadoxin for its approved uses, such as high blood pressure and BPH, is generally considered a long-term course. This sustained administration is designed to help manage these chronic conditions over time.


Q: Is this drug effective for 24 hours?

Official pharmacological information shows the drug has an elimination half-life of approximately 22 hours. This figure describes the time it takes for the amount of medication in the body to drop by half, which is consistent with its once-daily dosing schedule.


Q: What should I do if I miss a dose of Alfadoxin?

Official regulatory guidance suggests that double doses should be avoided. If it is nearly time for the next scheduled dose, skipping the missed one is generally advised. Consult the official product label for detailed guidance on managing a missed dose.


Q: Is Alfadoxin suitable for older adults?

Regulatory advisory groups state that non-selective alpha-1 blockers, including this medication, should generally be avoided for treating high blood pressure in older adults. This warning is due to the elevated risk of low blood pressure upon standing, known as orthostatic hypotension.


Q: Does Alfadoxin have any effect on other secondary conditions, like cholesterol?

Official studies show the drug has produced small reductions in total serum cholesterol and LDL ('bad') cholesterol. However, regulatory documents state that the full clinical significance of these effects on cholesterol levels is currently uncertain.


Q: What is the difference between generic Alfadoxin and the brand name version?

The active substance in Alfadoxin is doxazosin mesylate, which is the generic name. The medication is also sold under common brand names like Cardura and Cardura XL. Generic versions of the drug are generally available.


Q: Is Alfadoxin a controlled substance?

Regulatory classifications indicate that Alfadoxin is not included on the list of controlled substances. This means the medication is not subject to special rules that apply to drugs with a potential for abuse or dependence.


Q: Can I drive or operate heavy machinery while taking Alfadoxin?

Official product warnings advise against driving or operating machinery until it is known how the medication affects the individual, as symptoms such as dizziness, drowsiness, or light-headedness may occur.


Q: What should I do in the case of an overdose?

Regulatory documents advise that overdose symptoms can include excessive drowsiness, dizziness, fainting, or seizure. In the event of a suspected overdose, it is advised to contact emergency medical services or a poison control center immediately.


Q: What will happen if I stop taking Alfadoxin suddenly?

Official guidelines caution that suddenly stopping this medication can cause your underlying medical condition to become worse. Official guidelines recommend consultation with a healthcare provider before making any changes to the treatment plan.


Q: What are the most common reasons patients stop taking Alfadoxin in clinical trials?

Data from clinical trials show that common side effects led some patients to stop taking the drug. The most frequent reasons for discontinuation included dizziness, fatigue, and low blood pressure upon standing (postural hypotension).


Q: Is Alfadoxin available over-the-counter or does it require a prescription?

Regulatory databases confirm that Alfadoxin is categorized as a prescription-only medication ( Rx-only). It is not available for purchase over-the-counter.


Q: I feel nauseous after taking the pill. Is that normal?

Official safety resources recognize that feeling sick or nauseous is a potential side effect of the medication. Taking the medicine after eating may help reduce feelings of nausea.


Q: Does Alfadoxin affect the results of any lab tests?

According to information published in medical journals, this type of medication is considered one of the least interfering drugs for the specific blood tests used to diagnose a condition called Primary Aldosteronism. It is generally advised to inform laboratory personnel about all medications being taken.

How should Alfadoxin be stored and disposed of?

The storage and disposal of Alfadoxin (Doxazosin) must adhere strictly to regulatory requirements to maintain product integrity and ensure safety.

Official Storage Conditions

Alfadoxin tablets must be stored at controlled room temperature, typically between 20°C and 25°C (68°F and 77°F). It is mandatory to keep the container tightly closed and away from excessive heat, moisture, and light. The medicine must not be frozen.

Packaging and Child Safety

For child protection, the product must be kept in the container it came in, with the safety cap secured, and stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Alfadoxin should not be flushed down the toilet or drain. Official instructions recommend utilizing a drug take-back program for disposal. If a take-back program is unavailable, the alternative is to mix the tablets with an undesirable substance (such as coffee grounds) and seal the mixture in a container before discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alfadoxin found in:

A-Z Index: